Japanese pharmaceutical company Kyowa Kirin has completed its acquisition of Orchard Therapeutics.

The acquisition will allow Kyowa Kirin to expand its portfolio and develop promising gene therapy candidates.

The partnership will focus on developing gene therapies for three undisclosed rare diseases.

Orchard Therapeutics' CEO, Bobby Gaspar, will report to Kyowa Kirin's President and join the company's senior R&D leadership team.

The collaboration aims to leverage Orchard's gene therapy platform and Kyowa Kirin's drug discovery and development expertise.

Both companies are dedicated to advancing the field of gene therapy and improving the lives of patients with rare diseases.